Evidence map›Paper›PMID 29459207›Full record

ArticleBioorganic & medicinal chemistry letters2018

A small group of sulfated benzofurans induces steady-state submaximal inhibition of thrombin.

Daniel K Afosah, Stephen Verespy, Rami A Al-Horani, Rio S Boothello, Rajesh Karuturi, Umesh R Desai

Open access · bronzeAbstract read
In one paragraph

Article in Bioorganic & medicinal chemistry letters, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
1.3field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 18 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. Article
  9. Article
  10. Article
  11. Review
  12. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Daniel K AfosahDepartment of Medicinal Chemistry, Virginia Commonwealth University, Richmond, VA, USA; Institute for Structural Biology, Drug Discovery and Development, Virginia Commonwealth University, Richmond, VA, USA.
Stephen VerespyInstitute for Structural Biology, Drug Discovery and Development, Virginia Commonwealth University, Richmond, VA, USA; Department of Chemistry, Virginia Commonwealth University, Richmond, VA, USA.
Rami A Al-HoraniInstitute for Structural Biology, Drug Discovery and Development, Virginia Commonwealth University, Richmond, VA, USA; Division of Basic Pharmaceutical Sciences, Xavier University, New Orleans, LA, USA.
Rio S BoothelloInstitute for Structural Biology, Drug Discovery and Development, Virginia Commonwealth University, Richmond, VA, USA.
Rajesh KaruturiInstitute for Structural Biology, Drug Discovery and Development, Virginia Commonwealth University, Richmond, VA, USA.
Umesh R DesaiDepartment of Medicinal Chemistry, Virginia Commonwealth University, Richmond, VA, USA; Institute for Structural Biology, Drug Discovery and Development, Virginia Commonwealth University, Richmond, VA, USA. Electronic address: urdesai@vcu.edu.
Virginia Commonwealth University · USXavier University · US

Funding

Therapeutic assessment of synthetic heparin sulfates in transplantation modelsP01HL107152 · NHLBI · VIRGINIA COMMONWEALTH UNIVERSITY · PI DESAI, UMESH RAMANLAL · 2011 to 2017
$15.8M
Dual Direct Inhibitors of Thrombin and Factor XaR01HL090586 · NHLBI · VIRGINIA COMMONWEALTH UNIVERSITY · PI DESAI, UMESH RAMANLAL · 2009 to 2018
$3.9M
Advanced Skills Development in Glyco-Hematology and Glyco-OncologyR25HL128639 · NHLBI · VIRGINIA COMMONWEALTH UNIVERSITY · PI DESAI, UMESH RAMANLAL · 2015 to 2019
$613k
NHLBI NIH HHS P01 HL107152NHLBI NIH HHS R01 HL090586NHLBI NIH HHS R25 HL128639
6 · The paper itself

Abstract

Despite the development of promising direct oral anticoagulants, which are all orthosteric inhibitors, a sizable number of patients suffer from bleeding complications. We have hypothesized that allosterism based on the heparin-binding exosites presents a major opportunity to induce sub-maximal inhibition of coagulation proteases, thereby avoiding/reducing bleeding risk. We present the design of a group of sulfated benzofuran dimers that display heparin-binding site-dependent partial allosteric inhibition of thrombin against fibrinogen (ΔY = 55-75%), the first time that a small molecule (MW  < 800) has been found to thwart macromolecular cleavage by a monomeric protease in a controlled manner. The work leads to the promising concept that it should be possible to develop allosteric inhibitors that reduce clotting, but do not completely eliminate it, thereby avoiding major bleeding complications that beset anticoagulants today.

Indexed as

BenzofuransDose-Response Relationship, DrugHumansMolecular StructureSerine Proteinase InhibitorsSmall Molecule LibrariesStructure-Activity RelationshipSulfatesThrombinBenzofuransSerine Proteinase InhibitorsSmall Molecule LibrariesSulfatesThrombinAllosteric inhibitionAnticoagulantsEnzyme regulationHeparin-binding siteThrombin

Identifiers

PMID29459207
PMCPMC5851871
OpenAlexW2789296450

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.